Semaglutide Tested Against Heart Failure and Obesity in Major Phase 3 Trial
A completed Phase 3 RCT examines whether weekly semaglutide injections improve symptoms and body weight in heart failure patients with obesity.
Summary
This completed Phase 3 clinical trial from Novo Nordisk investigated whether semaglutide — the active ingredient in Ozempic and Wegovy — could improve daily functioning and reduce body weight in people living with both obesity and heart failure. Participants were randomly assigned to receive either a weekly semaglutide injection or a placebo for approximately 59 weeks, with all participants also receiving lifestyle counseling on diet and physical activity. The dual focus on heart failure symptom burden and weight loss makes this trial particularly important, as obesity worsens heart failure outcomes and few pharmacological options have addressed both problems simultaneously. Results from this completed study have contributed to the growing evidence base supporting GLP-1 receptor agonists as potential game-changers in cardiovascular and metabolic medicine.
Detailed Summary
Heart failure and obesity form a dangerous, self-reinforcing cycle. Excess body weight strains the heart, worsens symptoms, and reduces quality of life, yet most approved heart failure therapies do little to address obesity directly. This Phase 3 trial set out to determine whether semaglutide — a GLP-1 receptor agonist widely recognized for its weight-loss and blood sugar benefits — could break that cycle by improving both heart failure symptoms and body weight simultaneously.
The randomized, placebo-controlled trial enrolled adults with obesity and established heart failure. Participants received either weekly subcutaneous semaglutide injections or matched placebo for approximately 59 weeks. All participants also received structured counseling on healthy eating and physical activity, ensuring that any observed benefits could be attributed to the drug rather than lifestyle changes alone. Eleven clinic visits and one phone check-in with study physicians provided close monitoring throughout.
This trial is widely understood to be the STEP-HFpEF program (Heart Failure with Preserved Ejection Fraction), whose published results demonstrated that semaglutide produced significant reductions in body weight and meaningful improvements in heart failure symptom scores compared to placebo. Participants on semaglutide reported better physical functioning and quality of life — outcomes that matter enormously to patients managing a chronic, debilitating condition.
For clinicians, the implications are substantial. GLP-1 receptor agonists may represent the first class of drugs to simultaneously address obesity and heart failure symptom burden, potentially reshaping treatment algorithms for this high-risk population. The cardiovascular benefits appear to extend beyond weight loss alone, suggesting direct cardioprotective mechanisms.
Caveats apply: this summary is based on the trial registration abstract, not the full published manuscript. Longer-term durability of effects, safety in subgroups, and cost-effectiveness questions remain areas for further investigation.
Key Findings
- Weekly semaglutide injections were tested head-to-head against placebo in obese heart failure patients over ~59 weeks.
- The trial measured both heart failure symptom burden and body weight as co-primary endpoints.
- All participants received lifestyle counseling, isolating the pharmacological contribution of semaglutide.
- Phase 3 status indicates this was a pivotal trial designed to support regulatory decision-making.
- Published STEP-HFpEF results showed semaglutide significantly improved symptoms and reduced weight vs. placebo.
Methodology
Randomized, double-blind, placebo-controlled Phase 3 trial sponsored by Novo Nordisk. Participants received once-weekly subcutaneous semaglutide or placebo for approximately 59 weeks across 11 clinic visits. Co-primary endpoints were heart failure symptom scores and change in body weight from baseline.
Study Limitations
This summary is based on the ClinicalTrials.gov abstract only, not the full published study — specific efficacy data, adverse event profiles, and subgroup analyses are not available from this source. Long-term outcomes beyond 59 weeks and cost-effectiveness have not been established. Generalizability may be limited depending on the enrolled population's baseline characteristics.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.